EUCTR2005-002778-30-FI进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired Glucose Tolerance (IGT)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Male, non-fertile female or female of childbearing potential using a medically approved birth control method.
- •A non-fertile female is defined as: post menopausal (12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m); 6 weeks post bilateral oophorectomy with or without hysterectomy; post hysterectomy; or sterilized by tubal ligation.
- •A female of childbearing potential is defined as any woman physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means.
- •Medically approved birth control method include: hormonal contraceptives, IUD, and double-barrier contraception. Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the subject ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Reliable contraception should be maintained throughout the study.
- •2.Age in the range of 18 to 80 years inclusive.
- •3.Body mass index (BMI) in the range of 23-45 kg/m2 inclusive at visit 1.
- •4.Impaired glucose tolerances (IGT) as defined as: FPG < 126 mg/dL (7.0 mmol/L) and 2-hr post-challenge plasma glucose (after a 75-g OGTT) = 140 mg/dL (7.8 mmol/L) and < 200 mg/dL (11.1 mmol/L)
- •5.Agreement to maintain prior diet and exercise habits during the full course of the study.
- •6.Written informed consent to participate in the study.
- •7.Ability to comply with all study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or lactating female.
- •2.Diabetes, defined as any of the following:
- •FPG = 126mg/dL (7.0 mmol/L) at visit 1.
- •2-hr post-challenge plasma glucose (after a 75-g OGTT) = 200 mg/dL (11.1 mmol/L) at visit 1.
- •Diabetes diagnosed by a physician and confirmed by other clinical data, other than gestational diabetes.
- •Use of insulin or any oral antidiabetic agents prior to visit 1, other than during pregnancy.
- •3.Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.
- •4.A history of:
- •Torsades de Pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.
- •percutaneous coronary intervention within the past 3 months.
- •any of the following within the past 6 months: myocardial infarction (MI) (If the visit 1 ECG reveals patterns consistent with a MI and the date of the event cannot be determined, then the subject can enter the study at the discretion of the investigator and the sponsor); coronary artery bypass surgery; unstable angina; or stroke.
- •5.Congestive heart failure NYHA class III or IV.
- •6.Any of the following ECG abnormalities:
- •second degree AV block (Mobitz 1 and 2)
- •third degree AV block
- •prolonged QTc (> 500 msec)
- •7.Malignancy including leukemia and lymphoma (not including basal cell skin cancer) within the last 5 years.
- •8.Liver disease such as cirrhosis or chronic active hepatitis.
- •9.Significant renal dysfunction (see also exclusion criteria # 18 laboratory abnormalities).
- •10.Acromegaly or treatment with growth hormone or similar drugs.
- •11.Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
- •12.Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
- •13.Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
- •14.Treatment with class Ia, Ib and Ic or III anti-arrhythmics.
- •15.Thyroid hormone replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within normal limits at visit 1.
- •16.Use of other investigational drugs at visit 1, or within 30 days or 5 half-lives of visit 1, whichever is longer, unless local health authority guidelines mandate a longer period.
- •17.Treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months (i.e., cytostatic drugs).
- •18.Any of the following significant laboratory abnormalities:
- •ALT, AST greater than 3 times the upper limit of the normal range at visit 1.
- •Direct bilirubin greater than 1.3 times the upper limit of the normal range at visit 1.
- •Serum creatinine levels = 2.5 mg/dl (220 µmol/l) at visit 1.
- •TSH outside normal range at visit 1.
- •Clinically significant laboratory abnormalities, confirmed by repeat measurement at visit 1.
研究者
相似试验
未知
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg compared with Leuprorelin in the Treatment of Uterine Fibroidsterine fibroidJPRN-jRCT2080223074Takeda Pharmaceutical Company Limited288
进行中（未招募）
1 期
A clinical trial of TEV-48125 to evaluate long term safety, tolerability and efficacy for the Preventive Treatment of MigraineEpisodic and Chronic MigraineMedDRA version: 20.0 Level: LLT Classification code 10066636 Term: Chronic migraine System Organ Class: 100000004852MedDRA version: 20.0 Level: LLT Classification code 10027602 Term: Migraine headache System Organ Class: 100000004852EUCTR2015-004550-18-FITeva Branded Pharmaceutical Products R&D, Inc.1,890
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple SclerosisEUCTR2008-006333-27-EEBiogen Idec Limited1,500
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's DiseaseCrohn's DiseaseEUCTR2020-004775-40-LVArena Pharmaceuticals Inc.1,265
进行中（未招募）
1 期
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine Treatmentsepisodic and chronic migraineMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 100000004852EUCTR2017-002441-30-SETeva Branded Pharmaceutical Products R&D, Inc.838